Revefenacin, a Once-Daily, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease (COPD): Results of a 52-Week Safety and Tolerability Phase 3 Trial in Participants with Moderate to Very Severe COPD [Board No. 613]